PledPharma AB has together with Linköping University and Ryhov County Hospital in Jönköping received 300 000 Swedish kronor from the Research Council of the South East Sweden (FORSS) to test mangafodipir (PP-095) in patients with colon cancer going through cytostatic treatment.
The clinical trials will test whether the PLED-derivative PP-095 reduces the frequency and severity of side effects during chemotherapy in cancer patients. Professor Ursula Falkmer at the Oncology Department at Ryhov County Hospital will serve as the principal investigator in the clinical studies.
Preclinical research has shown that PP-095 protects normal cells and tissues without loss of anti-tumour activity during cytostatic treatment.
The research group is very pleased to have received this research grant from FORSS, says Assistant Professor Jan Olof G. Karlsson, responsible for R&D at PledPharma AB.
Accelerator Nordic AB has an active majority ownership position in a number of development companies within Bio Pharma and Medical Technology. The Accelerator group is addressing large growth markets as oncology, imaging and the orthopaedic market. The group has a business model based on licensing. Accelerator focuses on projects in the stage of verification where there is a clear unmet need and large industrial players. Accelerator Nordic AB is a publicly listed company traded on the Aktietorget exchange in Stockholm, Sweden.
For more information, please visit, www.acceleratorab.se
PledPharma AB develops new pharmaceutical applications based on a clinically approved PLED-derivative, PP-095, with an initial candidate for oncology that already has entered Clinical Phase II trials. PledPharma’s core technology is an omnipotent catalytic antioxidant that has characteristics that protect healthy cells during cancer treatment with chemotherapy and/or radiation. When used as an adjunct treatment, it has the potential to improve both clinical outcomes and patient well-being. In addition to cancer treatment, catalytic antioxidants have a wide range of potential indications, e.g., myocardial infarction, stroke and neurodegenerative diseases.
For more information, please visit www.pledpharma.se